AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Fulcrum Therapeutics, Inc.
Video analysis: FULC
All videosNo video analysis for this stock yet. Request one from our team.
News: FULC
Kaplan Fox Urges Investors of Fulcrum Therapeutics, Inc. (FULC) with Losses to Contact the Firm
New York, New York--(Newsfile Corp. - September 10, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)
BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (FULC) of an Ongoing Securities Investigation
New York, New York--(Newsfile Corp. - September 8, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) and Slate Medicines, Inc. Upon closing o
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) and Slate Medicines, Inc. Upon closing of the proposed transaction, Fulcrum shareholders are expected to own 5.0% of the combined company.Halper Sadeh encourages Fulcrum shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@.
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) on Behalf of Shareholders for Possible Securities Law Violations
New York, New York--(Newsfile Corp. - September 4, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
Kaplan Fox Advises Investors of Fulcrum Therapeutics, Inc. (FULC) to Contact the Firm Regarding a Securities Investigation
New York, New York--(Newsfile Corp. - September 2, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
BlackRock Inc. Acquires Shares of 8,824,259 Fulcrum Therapeutics, Inc. $FULC
BlackRock Inc. bought a new position in Fulcrum Therapeutics, Inc. (NASDAQ: FULC) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 8,824,259 shares of the company's stock, valued at approximately $32,297,000. BlackRock Inc. owned approximately 11.57% of Fulcrum Therapeutics at
